CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Phase 3 randomised study of canfosfamide (Telcyta\uae, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer
Authors
G. Brown
J. del Campo
+10Â more
N. Finkler
J. Hunter
M. Jones
J. Kavanagh
S. Kaye
A. Lohr
D. Matei
L. Meng
I. Vergote
Jan Baptist Vermorken
Publication date
1 January 2009
Publisher
Abstract
Abstract is not available.
Similar works
Full text
Available Versions
Institutional Repository Universiteit Antwerpen
See this paper in CORE
Go to the repository landing page
Download from data provider
c:irua:78145
Last time updated on 25/02/2019